Citius Pharmaceuticals Inc
citiuspharma.comCitius Pharmaceuticals Inc (NASDAQ: CTXR) is a pre-revenue clinical-stage pharmaceutical company developing prescription drug candidates for unmet medical needs. The company generates no product revenue, funding operations through equity issuances, including common stock sales, at-the-market offerings, and preferred stock transactions, as disclosed in the 10-K filed December 23, 2025. Its pipeline includes Mino-Lok, an antibiotic lock solution targeting catheter-related bloodstream infections, and Halo-Lido, a topical corticosteroid-lidocaine combination product for hemorrhoid treatment. A subsidiary, Citius Oncology, holds LYMPHIR, an approved oncology product. A second subsidiary, NoveCite, is developing mesenchymal stem cell therapies. The company has incurred net losses of $39,740,269 and $39,425,839 for the fiscal years ended September 30, 2025 and September 30, 2024, respectively, and carried an accumulated deficit of $238,804,129 as of September 30, 2025. The independent auditor issued a going-concern emphasis in the FY2025 audit report.
Products & Services
Mino-Lok: antibiotic lock solution targeting catheter-related bloodstream infections in short-term and long-term central venous catheter patients. Halo-Lido: topical corticosteroid-lidocaine combination in development for hemorrhoid treatment, targeting FDA approval and three-year market exclusivity. LYMPHIR: approved oncology product held by subsidiary Citius Oncology. NoveCite: mesenchymal stem cell therapy programs at subsidiary level.
Revenue Model
No product revenue reported in the 10-K filed December 23, 2025. Operations are funded through equity capital raises: common stock sales, at-the-market offerings, pre-funded warrant exercises, and preferred stock issuances. In FY2024, the company recognized $2,387,842 from selling New Jersey income tax net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program.
Customers & Markets
Target end markets include hospital and outpatient settings treating catheter-related bloodstream infections and patients with Grade I through Grade IV hemorrhoids. Oncology patients are the end market for LYMPHIR via Citius Oncology. No commercial customer relationships are disclosed in the filing excerpts.
Geographic Exposure
Regulatory filings reference FDA approval pathways, indicating a primary U.S. commercial focus. No international revenue or geographic segment data disclosed in the filing excerpts.
Financial Snapshot
Loading...
